Rapport Therapeutics Raises Over $400 Million in Capital Offerings

Rapport Therapeutics completed a financing transaction on October 30, 2026, to fund clinical trials, research and development, and general corporate purposes. It expects approximately $215.7 million in net proceeds from a public stock and pre-funded warrant offering and $166.8 million from $172.5 million of 2.25% convertible senior notes due 2032, alongside a $30 million private placement. Morgan Stanley, Leerink Partners, and Evercore underwrote the offerings; the article does not report a stock-price reaction.